Cellular Senescence and Skin Aging: The Science Behind Why Lasers Work Longer Than You Think

By Dr. Cameron Chesnut | Five Codes Podcast featuring Dr. Ryan Kelm

Most people think about what a laser or energy-based device does in the first few weeks after treatment. The skin tightens a little. Fine lines soften. Texture improves. The result is visible and then, over time, it fades as aging continues.

That is an accurate description of what most patients experience. But it is not the whole picture of what is happening biologically, and it may actually be underselling the most important benefit of these treatments by a significant margin.

Dr. Ryan Kelm spent his Harvard Laser Fellowship not just learning how to operate devices but researching a question that barely gets discussed in patient-facing conversations: what are these devices actually doing to the biology of aging itself? His answer involves zombie cells, chronic inflammation, distant organ dysfunction, and a concept called cellular senescence that sits at the center of how and why we age.

What Is Cellular Senescence?

Cellular senescence is a state in which a cell has stopped dividing but has not died. It is still metabolically active. It is still releasing signaling molecules into its environment. It is just no longer doing the work it was designed to do, and it refuses to leave.

These are the zombie cells. The technical term for what they secrete is the senescence-associated secretory phenotype, or SASP. The SASP is a cocktail of pro-inflammatory cytokines, enzymes, and growth factors that create a persistently inflammatory local environment. As we age, senescent cells accumulate throughout the body, and the low-grade chronic inflammation they produce is increasingly recognized as one of the central drivers of age-related disease, not just in the skin but systemically.

In the dermis specifically, the key cell is the fibroblast. Fibroblasts produce collagen, elastin, and hyaluronic acid. They maintain the extracellular matrix that gives skin its structure, resilience, and youthful quality. As fibroblasts become senescent, they stop doing those jobs effectively. Their communication with adjacent cells becomes inefficient, like a highway that used to carry dense, organized traffic and now sees occasional cars going in unpredictable directions. When fibroblasts can no longer communicate well with the melanocytes above them, those cells can no longer respond appropriately to UV damage, and that is one of the mechanisms by which senescent skin becomes more vulnerable to skin cancer over time.

The accumulation of senescent cells in skin is not just a local problem. Studies in mice have demonstrated that transplanting senescent cells into young animals produces dysfunction not just in nearby skin but in distant organs: the liver, skeletal muscle, and hippocampus were all affected. Grip strength declined. Frailty increased. The inflammatory signaling from senescent skin cells circulates systemically, and that circulation touches everything.

What Devices Are Actually Doing

Dr. Kelm and his co-fellow wrote a systematic review of every published paper examining the relationship between energy-based devices and cellular senescence. The question was simple: do these devices affect senescence, and if so, how?

Every single device they examined showed an impact. CO2 lasers, erbium, 1927 nm, 1550 nm, pulsed dye laser, Q-switch, RF microneedling, ultrasound, IPL. Every one of them produced a measurable reduction in biomarkers of cellular senescence.

This reframes the conversation about what devices are for in an important way. We have always talked about what a CO2 laser does in terms of visible surface outcomes: smoother skin, reduced wrinkles, improved tone. What the literature is now showing is that the mechanism runs deeper. By creating controlled wounding and a regenerative response, these devices are clearing out and reinvigorating the fibroblast population, reducing the SASP burden, and re-establishing cell communication pathways that had become sluggish or dysfunctional.

The IPL data is particularly interesting. IPL treatment is the only one for which researchers have looked specifically at the gene expression profile of treated skin, and what they found is that IPL-treated skin showed a gene expression pattern resembling younger skin. The cells were not just less inflamed. They were operating more like they had years ago.

For a deeper read: Dr. Kelm's systematic review is published in Aesthetic Surgery Journal. The Harvard-affiliated research on pulsed dye laser and non-ablative lasers reducing future skin cancer risk is part of this growing body of evidence that controlled wounding has biological effects well beyond what is visible at the surface.

The Pre-Juvenation Concept

The traditional model for how devices fit into an aesthetic practice is as maintenance tools. You have surgery or a significant procedure, you achieve a new baseline, and then devices help slow down the aging curve from that new point forward.

That model is still correct. But Dr. Kelm introduced a concept during our conversation that I found genuinely paradigm-shifting: pre-juvenation.

If devices reduce cellular senescence, and senescence is one of the primary drivers of the rate at which we age, then there is a legitimate case for using these technologies before the visible signs of aging have accumulated significantly — not to treat something that already looks wrong, but to modulate the underlying biology that will determine how quickly things go wrong.

The traditional framing is reactive: I see a problem, I treat a problem. Pre-juvenation is proactive: I understand the biology of what causes visible change over time, and I intervene at that biological level before the surface expression makes it unavoidable.

This does not mean aggressive ablative CO2 resurfacing on a 28-year-old. It means thinking about the appropriate device at the appropriate settings to create the kind of controlled wounding that reinvigorates fibroblast populations and clears the senescent cell burden before it accumulates to the point where it is running the show. RF microneedling in younger patients, used conservatively and correctly, fits into this framework. Milder non-ablative fractional treatments fit into it as well. The goal is biological maintenance, not dramatic visible correction.

The Skin Cancer Connection

One of the most clinically significant findings in this literature is the reduction in future skin cancer risk associated with laser treatments. This has been observed specifically with non-ablative fractional lasers and pulsed dye laser, and the mechanism tracks directly back to senescence.

When dermal fibroblasts are senescent, they cannot communicate effectively with the keratinocytes above them. Those keratinocytes lose the ability to respond appropriately to UV-induced DNA damage. Mutations occur and are not cleared. Skin cancer risk rises not because of direct UV damage alone, but because the cellular support infrastructure for detecting and responding to that damage has broken down.

When laser treatment reinvigorates the fibroblast population and clears senescent cells, that communication pathway is restored. Keratinocytes can respond to UV damage the way they are supposed to. This is not a theoretical extrapolation. There is published data showing reduced incidence of future actinic keratoses and skin cancers in patients who have received non-ablative laser treatments.

For anyone with a history of significant sun exposure, this changes the calculus around laser resurfacing from a purely aesthetic intervention to something that has legitimate preventive medicine value.

The Collagen Problem

There is a habit in the device world of measuring outcomes in terms of collagen. A treatment increases collagen production, and that is presented as the marker of success. Dr. Kelm's view, and mine, is that collagen gets far too much of the credit and elastin is the under-appreciated story.

Elastin is what gives skin its bounce, its recoil, its ability to spring back after movement. It is extraordinarily slow to regenerate. Its half-life is measured in decades. Once elastin is degraded, it accumulates as fragmented byproducts in the dermis, and those byproducts are not just useless — they can interfere with new elastin synthesis and contribute to the chronically pro-inflammatory environment that drives further senescence.

What some devices are doing, when used correctly and with appropriate settings, is stimulating cells to clear those elastin degradation products and upregulate the precursors for new elastin synthesis. This is not the same as simply increasing collagen. It is qualitatively different work, and it produces a qualitatively different outcome: skin that has resilience and dynamic movement, not just density and firmness.

This is also one of the reasons that fat transfer in combination with laser produces results that neither achieves alone. Fat contains adipose-derived stem cells that, when transferred, have been shown in animal studies to restructure the dermis in ways that specifically address elastin. The recycling of degraded elastin byproducts and the upregulation of elastin precursors are both enhanced when fat and laser are combined. We discuss this further in the future of fat transfer post.

A Thought Experiment Worth Sitting With

Dr. Kelm raised a hypothesis that I think deserves serious consideration. The skin is the largest organ in the body. It accumulates senescent cells as a consequence of decades of UV exposure, pollution, microplastic exposure, and ordinary aging. The SASP signaling from those cells circulates systemically and touches distant organs.

What if addressing the senescent cell burden in skin at scale had effects on distant organ aging? Not just on how the skin looks, but on the inflammatory milieu that reaches the liver, the muscle, the brain? The mouse studies transplanting senescent cells and producing distant organ dysfunction suggest the mechanism is plausible. The inverse, clearing senescent cells from a major organ, might have effects that go in the other direction.

This is speculative. The human data does not exist yet. But the directionality of the existing evidence, combined with what we now understand about how senescent cells communicate, makes it a hypothesis worth taking seriously. It also puts even modest skin-focused treatments in a different frame. The question is no longer just "does this look better," but "what is this doing to the underlying biology of aging, and does that matter beyond the mirror?"

Why Evidence-Based Medicine Is More Than Randomized Controlled Trials

One theme that kept coming up in my conversation with Dr. Kelm is the relationship between clinical observation, mechanistic science, animal data, and the large randomized controlled trials that the field tends to require before it accepts something as settled.

Photobiomodulation, which we cover in depth in the red light therapy series, was called junk science at a Harvard conference right around when Dr. Kelm was training there. One key opinion leader's dismissal suppressed publication and uptake for years. The mechanistic data was strong, the animal data was strong, the clinical observations were consistent — but without the blessing of a tier-one trial, it was marginalized.

The evidence has since fully caught up, and the consensus has flipped so completely that not using photobiomodulation is arguably the thing that needs defending now. The same pattern is playing out with cellular senescence, with pre-juvenation concepts, and with some of the regenerative surgery approaches Dr. Kelm and I both practice.

Evidence-based medicine is often interpreted as meaning "wait for the randomized controlled trial." That is a reasonable standard for drug approvals. It is a limiting framework when the mechanism is well-understood, the cell and animal data are consistent, the clinical observations align, and the potential for harm is low. The right question is not only "has this been proven in a phase three trial?" It is "what does the totality of the evidence say, and what is the risk of acting on it now versus waiting for a higher tier of data that may never come?"

Frequently Asked Questions

What are zombie cells, and why do they matter for skin aging?

Zombie cells are senescent cells: cells that have stopped dividing but are still metabolically active, releasing pro-inflammatory signaling molecules called the senescence-associated secretory phenotype (SASP). As they accumulate in the dermis over time, they create a chronically inflammatory environment that degrades fibroblast function, impairs collagen and elastin production, reduces the skin's ability to respond to UV damage, and contributes to systemic inflammation that affects distant organs. Reducing the burden of senescent cells in skin is increasingly understood to be one of the most meaningful things that can be done to address the biology of skin aging.

Do lasers actually slow skin aging, or just improve how it looks now?

Both. The visible changes after laser treatment are real and clinically meaningful. But the emerging evidence on cellular senescence suggests that the deeper mechanism involves clearing senescent cells, reinvigorating fibroblast populations, restoring cell communication pathways, and reducing the SASP burden that drives ongoing aging. A systematic review of every energy-based device in the published literature found that each one produced measurable reductions in senescence biomarkers. The implication is that the benefits of treatment extend well beyond what is visible at the skin surface in the weeks after the procedure.

What is pre-juvenation?

Pre-juvenation is the use of devices and treatments to intervene in the biological mechanisms of aging before visible changes have accumulated significantly. Rather than treating a problem that already looks wrong, pre-juvenation targets the cellular biology, particularly senescent cell burden, before it reaches the level where it is driving obvious visible aging. It requires appropriate device selection, conservative settings calibrated to the patient's age and skin status, and a mindset shift from reactive treatment to proactive biological maintenance.

Why does everyone focus on collagen when elastin matters more?

Collagen is easier to measure and has historically been the standard endpoint in device research. Elastin is slower to regenerate, harder to study, and its degradation products accumulate in the dermis in ways that are not immediately visible but that contribute to ongoing inflammation and loss of skin resilience. A face that has good collagen density but poor elastin content looks dense and somewhat firm but lacks the spring, dynamism, and natural movement that characterizes genuinely youthful skin. Treatments that address both, including certain laser protocols and fat transfer, produce qualitatively different outcomes than those that only drive collagen.

Can treating skin reduce aging in other parts of the body?

The honest answer is that the human evidence for this does not yet exist. What does exist is mouse data showing that transplanting senescent cells into young animals produces distant organ dysfunction in the liver, muscle, and brain. The SASP signaling from senescent cells is systemic, not local. If the inverse is also true, if clearing the senescent cell burden from a large organ like the skin reduces circulating SASP and thereby reduces its downstream effects, the implications would extend well beyond aesthetics. This is currently a hypothesis supported by mechanism and animal models, not a proven clinical finding. It is worth knowing about and worth tracking as the evidence develops.

Listen to the Full Episode

🎧 Listen on Spotify🍎 Listen on Apple Podcasts▶️ Watch on YouTube

Related reading:

• Do Skin Tightening Devices Actually Work? A Harvard-Trained Laser Expert Answers
• The Future of Fat Transfer and Facial Lifting
• Laser Resurfacing at 5C
• What Is Red Light Therapy? A Surgeon's Complete Guide
• Red Light Therapy for Skin: Collagen, Elastin, and Anti-Aging
• Stem Cell-Rich Fat Transfer
• Collagen vs Elastin: Which Matters More for Anti-Aging?
• PDGF: The Growth Factor Changing the Future of Regenerative Aesthetics

Dr. Cameron Chesnut is a facial plastic surgeon and founder of 5C. Dr. Ryan Kelm completed the Harvard Laser Fellowship and the 5C facial plastic surgery fellowship. Dr. Chesnut holds a clinical teaching affiliation with the University of Washington School of Medicine. The views expressed here are their own and are not affiliated with or representative of that affiliation. This content is for general educational purposes only and is not individual medical advice.

‍